CalliSpheres药物洗脱微球和空白微球经动脉化疗栓塞术治疗中晚期非小细胞肺癌的比较

doi:10.3969/j.issn.1006-5725.2024.01.006

摘要/Abstract

摘要：

目的回顾性分析并比较CalliSpheres药物洗脱微球和空白微球经支气管动脉化疗栓塞术治疗中晚期非小细胞肺癌的临床疗效。方法收集50例经放、化疗、靶向及免疫治疗后无效或复发的中晚期非小细胞肺癌患者，进行超选择性支气管动脉化疗栓塞治疗。通过回顾性分析，比较CalliSpheres药物洗脱微球和空白微球两组间肿瘤治疗有效率和生存期的差异。结果术后药物洗脱微球组PR、ORR、DCR均高于空白微球组，其中术后1个月两组间DCR差异有统计学意义（χ² = 4.08，P = 0.04）。术后药物洗脱微球组PD低于空白微球组；术后药物洗脱微球组的CEA、CYF、SCC均低于空白微球组，两组术后CEA、CYF、SCC均低于术前，其中两组间术后1个月CEA、CYF差异有统计学意义（P < 0.05）；药物洗脱微球组PFS、OS均高于空白微球组。结论 CalliSpheres药物洗脱微球相较于空白微球经动脉化疗栓塞术可更有效地提高肿瘤治疗有效率及延长生存时间，为其治疗中晚期非小细胞肺癌提供可靠的临床实践依据。

关键词: 非小细胞肺癌, 药物洗脱微球, 动脉化疗栓塞术

Abstract:

Objective To analyze and compare the clinical efficacy of CalliSpheres drug-eluting microspheres and blank microspheres in the treatment of advanced non-small cell lung cancer by bronchial arterial chemoembolization. Methods Fifty patients with advanced non-small cell lung cancer who had failed or relapsed after radiotherapy， chemotherapy， targeting and immunotherapy were collected and treated with super-selective bronchial artery chemoembolization. A retrospective analysis was conducted to compare the tumor response rate and survival between CalliSpheres drug-eluting and blank microspheres. Results The PR， ORR and DCR in the drug-eluted microsphere group were higher than those in the blank microsphere group， and there was a statistical difference in DCR between the two groups 1 month after surgery （χ² = 4.08， P = 0.04）. PD in the drug-eluted microsphere group was lower than that in the blank microsphere group. The CEA， CYF and SCC in the drug-eluted microsphere group after surgery were lower than those in the blank microsphere group， and the CEA， CYF and SCC in the two groups after surgery were lower than those before surgery， and there were statistical differences in CEA and CYF 1 month after surgery between the two groups. The PFS and OS in drug-eluted microsphere group were higher than those in blank microsphere group. Conclusion CalliSpheres drug-eluting microspheres could improve the effective rate of tumor treatment and prolong the survival time more effectively than the blank microspheres via arterial chemoembolization， providing reliable clinical practice basis for the treatment of advanced non-small cell lung cancer.

Key words: non-small cell lung cancer, drug-carrying microspheres, arterial chemoembolization

中图分类号:

R734.2

程瑞文,郝若冰,李平,张堃,邓梨平,曹亚衡,粟麟,沈宏荣. CalliSpheres药物洗脱微球和空白微球经动脉化疗栓塞术治疗中晚期非小细胞肺癌的比较[J]. 实用医学杂志, 2024, 40(1): 32-37.

Ruiwen CHENG,Ruobing HAO,Ping LI,Kun ZHANG,Liping DENG,Yaheng CAO,Lin SU,Hongrong. SHEN. Clinical efficacy of CalliSpheres drug⁃loaded microspheres versus blank microspheres in the treatment of advanced non⁃small cell lung cancer by transarterial chemoembolization[J]. The Journal of Practical Medicine, 2024, 40(1): 32-37.

图/表 6

表1

图1

图2

图3

表2

图4

参考文献 28

1	WOLF J， GARON E B， GROEN H J M，et al. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC： Results from the GEOMETRY mono-1 study［J］. Eur J Cancer， 2023， 183： 98-108.
2	SAAD M I， ROSE-JOHN S， JENKINS B J. ADAM17： Anemerging therapeutic target for lung cancer［J］. Cancers （Basel）， 2019，11（9 ）：1218.
3	武阳，陆翰杰，水会锋，等. 既往免疫经治的晚期非小细胞肺癌患者接受安罗替尼联合PD-1单抗的疗效及安全性［J］. 实用医学杂志， 2023， 39（5）： 572-578
4	FELICIANO J L， MCLOONE D， XU Y X， et al. Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1： Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer［J］. Front Oncol， 2022， 12： 1081729.
5	李思玲，商凯，黄鸿翔，等.放疗联合免疫治疗在非小细胞肺癌中的研究进展［J］. 实用医学杂志， 2022， 38 （23）： 3017-3022.
6	MOUNTZIOS G， PLANCHARD D， METRO G， et al. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era： The European EXOTIC Registry［J］. JTO Clin Res Rep， 2023， 4： 100433.
7	LI X B， YIN M P， XIE P F，et al. Bronchial Artery Chemoembolization for Hemoptysis in Advanced Primary Lung Cancer［J］. Clin Lung Cancer， 2022， 23： e203-e209.
8	JIN S Q， ZHAO H Y， BIN B， et al. Transcatheter arterial chemoembolization improves clinical efficacy and life quality of patients with lung cancer and reduces adverse reactions［J］. Am J Transl Res， 2021， 13： 10396-10403.
9	BOAS F E， KEMENY N E， SOFOCLEOUS C T，et al. Bronchial or Pulmonary Artery Chemoembolization for Unresectable and Unablatable Lung Metastases： A Phase I Clinical Trial［J］. Radiology， 2021， 301（2）： 474-484.
10	LI X B， YIN M P， XIE P F， et al. Self-Expandable Metallic Stent Implantation Combined With Bronchial Artery Infusion Chemoembolization in the Treatment of Lung Cancer With Complete Atelectasis［J］. Front Oncol， 2021， 11： 733510.
11	CHEN C， WANG W， YU Z， et al. Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage Ⅲ non-small cell lung cancer after failure of concurrent chemoradiotherapy［J］. Lung Cancer， 2020， 146： 290-296.
12	BIE Z X， LI Y M， LI B，et al.The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer［J］. Thorac Cancer，2019，10：1770-1778.
13	王革芳. 经导管动脉灌注化疗药物应用原则——中国肿瘤介入专家共识［J］. 介入放射学杂志，2017，26（11）：963-970.
14	LEE J S， CHOI H J， KIM B K， et al.The Modified Response Evaluation Criteria in Solid Tumors （RECIST） Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization［J］. Gut Liver， 2020， 14（6）：765-774.
15	郭立文，郑家平，郝伟远，等. 载药微球支气管动脉栓塞化疗治疗晚期非小细胞肺癌10例［J］. 介入放射学杂志，2021，30（1）： 24-28.：
16	ZHU J， ZHANG H P， JIANG S， et al.Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage Ⅲ squamous cell lung cancer［J］. Ther Adv Respir Dis， 2017， 11： 301-309.
17	JIN S Q， ZHAO H Y， BAI B， et al. Transcatheter arterial chemoembolization improves clinical efficacy and life quality ofpatients with lung cancer and reduces adverse reactions［J］. Am Transl Res，2021，13（9 ）：10396-10403.
18	BI Y H， REN K W， REN J Z， et al. Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma［J］. Front Pharmacol， 2022， 13： 923585.
19	WU B L， ZHOU J L， GONG H， et al. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma： a short-term efficacy and safety study［J］. World J Surg Oncol， 2018， 16（1）： 69.
20	MA X， ZHENG D， ZHANG J，et al. Clinical outcomes of vinorelbine loading CalliSpheres beads in the treatment of previously treated advanced lung cancer with progressive refractory obstructive atelectasis［J］. Front Bioeng Biotechnol， 2022， 10： 1088274.
21	LIU X， LIN H， WANG Q， et al. Drug-eluting beads bronchial arterial chemoembolization plus intercostals arterial infusion chemotherapy is effective and well-tolerated in treating non-small cell lung cancer patients with refractory malignant pleural effusion ［J］. Thorac Dis，2021，13（4）：2339-2350.
22	XU S， BIE Z X， LI Y M， et al. Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer： A Comparative Study［J］. Front Oncol， 2022，12：851830.
23	LIU J， ZHANG W， REN J， et al. Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer ［J］. Front Cell Dev Biol， 2021，9：768943.
24	BIE Z X， LI Y M， LI B， et al. The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer［J］. Thorac Cancer， 2019， 10： 1770-1778.
25	BI Y， ZHANG B， REN J， et al.Clinical outcomes of gemcitabine-loaded callispheres drug-eluting beads for patients with advanced and inoperable lung cancer： A case series study［J］. Front Pharmacol， 2022，13：992526.
26	ZHAO Y W， LIU S， QIN H， et al. Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life： A multicenter prospective study［J］. Front Oncol，2023，13：1110917.
27	WANG Z， NIU H， LI Z， et al. Superselective arterial embolization with drug-loaded microspheres for the treatment of unresectable breast cancer［J］. Gland Surg， 2019， 8： 740-747.
28	LIU H， LI Y， LI Z， et al. Bevacizumab loaded CalliSpheres^® bronchial arterial chemoembolization combined with immunotherapy and targeted therapy for advanced lung adenocarcinoma［J］. Front Pharmacol， 2023， 14： 1170344.

组别	性别		年龄（x ± s，岁）	肿瘤分期
组别	男	女	年龄（x ± s，岁）	Ⅲb	Ⅳa
药物洗脱微球组	22	3	67.6 ± 1.5	10	15
空白微球组	21	4	67.2 ± 1.5	12	13
t值/χ²值	0.001		0.941	0.325
P值	0.996		0.552	0.569

组别	例数	恶心呕吐	骨髓抑制	胸痛	发热	合计
药物洗脱微球组	25	7	2	2	0	11（44）
空白微球组	25	6	8	5	1	20（80）
χ²值						6.876
P值						0.009

[1]	李鑫盼,方懿,邱俊. CD3⁺/CD4⁺T淋巴细胞水平及中性粒细胞与淋巴细胞比值在放射性肺炎中的预测价值[J]. 实用医学杂志, 2024, 40(20): 2923-2928.
[2]	赵论,赵欣,林晨琛,付琪,石默晗,张浩然. miR-217靶向FOXO3影响非小细胞肺癌对吉非替尼耐药性及相关机制[J]. 实用医学杂志, 2024, 40(16): 2277-2283.
[3]	胡雪艳,孟凡亮,董娟娟. 不同病理分型的初治非小细胞肺癌骨转移患者的预后分析[J]. 实用医学杂志, 2024, 40(16): 2316-2325.
[4]	袁胜芳,王布,项保利,赵建清,沈晶晶,张志华. 外周血循环肿瘤DNA预测晚期非小细胞肺癌免疫治疗疗效及预后价值[J]. 实用医学杂志, 2024, 40(15): 2110-2115.
[5]	李玉婷,颜琦璐,宋启斌. 非小细胞肺癌表皮生长因子受体靶向治疗的研究进展[J]. 实用医学杂志, 2024, 40(15): 2166-2171.
[6]	马雪,周世辉. p62/SQSTM1在非小细胞肺癌细胞增殖和侵袭转移中的作用[J]. 实用医学杂志, 2024, 40(1): 13-18.
[7]	王鹏,姚苏梅,吕学东,陈金亮. Kruppel样因子14介导的JAK-STAT信号通路对非小细胞肺癌预后的影响[J]. 实用医学杂志, 2024, 40(1): 25-31.
[8]	王延,贺雅静,黄立娜,张玉文. 河南豫东地区661例非小细胞肺癌常见驱动基因突变分析[J]. 实用医学杂志, 2024, 40(1): 38-42.
[9]	杨昌恒,陈颖,张中元,马庆庆. 肺泡灌洗液外泌体表皮生长因子受体基因突变检测对晚期非小细胞肺癌患者的临床意义[J]. 实用医学杂志, 2024, 40(1): 48-52.
[10]	徐越,张言斌,苏珊. 基于转录组测序探究C-MET表达在非小细胞肺癌中的免疫调控机制[J]. 实用医学杂志, 2024, 40(1): 7-12.
[11]	吴凯怡吕学东何海艳陈金亮 . 冷冻消融联合免疫治疗在非小细胞肺癌治疗中的应用进展 [J]. 实用医学杂志, 2023, 39(8): 1058-1062.
[12]	吴玲红周敏卢瑶朱光炜 . 中性粒细胞/淋巴细胞比值及其变化值对肝细胞癌介入术后急性肝功能恶化风险的预测价值 [J]. 实用医学杂志, 2023, 39(6): 713-719.
[13]	叶华吴敬波 . 局部晚期非小细胞肺癌后装插植放疗[J]. 实用医学杂志, 2023, 39(5): 525-532.
[14]	邓建华陈瑞李道生段训凰 . ADGRD1抑制非小细胞肺癌细胞增殖和转移的作用及其分子机制[J]. 实用医学杂志, 2023, 39(5): 550-556.
[15]	王韵宋姗彭斐胡文霞 . LncRNA SNHG15通过miR⁃483⁃3p/DDIT4轴调节非小细胞肺癌细胞的顺铂敏感性和上皮间质转化 [J]. 实用医学杂志, 2023, 39(5): 557-563.